Dr. Reddy’s Launches First-to-Market OTC Olopatadine 0.7% Eye Drops in the U.S.
Dr. Reddy’s Laboratories Ltd. announced the first-to-market launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) in the United States, following approval from the U.S. Food and Drug Administration (USFDA). The product is the generic equivalent of Extra-Strength Pataday® (of Novartis AG) Once-Daily Relief, a leading over-the-counter antihistamine eye drop.




















